跳转至内容
Merck
所有图片(1)

文件

G5166

Sigma-Aldrich

糖苷酶F from Elizabethkingia miricola

buffered aqueous solution

别名:

N-糖苷酶 F, 肽N-糖苷酶

登录查看公司和协议定价
所有图片(1)

About This Item

CAS号:
83534-39-8
EC 号:
3.5.1.52 (BRENDA, IUBMB)
MDL號碼:
MFCD00131222
分類程式碼代碼:
12352204
NACRES:
NA.32

生物源

bacterial (Elizabethkingia miricola)

品質等級

200

共軛

(N-linked)

形狀

buffered aqueous solution

比活性

≥20000 units/mg protein

分子量

36 kDa

運輸包裝

wet ice

儲存溫度

2-8°C

相关类别

一般說明

PNGase F（肽N-糖苷酶F)剪切天冬酰胺连接糖蛋白，生成无糖肽链和分离的全长寡糖。

應用

PNGase F（来自米尔伊丽莎白菌）已用于蛋白的去糖基化。
用于使蛋白质脱糖基。

生化／生理作用

如果糖基化天冬酰胺基团在其氨基和羧基端被多肽链取代，则从糖蛋白中切割整个聚糖。

單位定義

一个单元将在37℃，pH7.5下通过SDS-PAGE监测，在1分钟内催化1纳摩尔变性核糖核酸酶B释放N-连接的寡糖。 PNGase F活性的一个 Sigma 单位等于1 IUB毫单位。

外觀

以溶于 20 mM Tris HCl (pH 7.5)、50 mM NaCl 和 1 mM EDTA 的溶液形式提供

象形圖

Health hazard
GHS08

訊號詞

Danger

危險聲明

H334

防範說明

P261 - P284 - P501

危險分類

Resp. Sens. 1

儲存類別代碼

12 - Non Combustible Liquids

水污染物質分類（WGK）

WGK 2

閃點（°F）

Not applicable

閃點（°C）

Not applicable

個人防護裝備

Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Ying-Nai Wang et al.
STAR protocols, 3(1), 101198-101198 (2022-03-05)
Immunotherapy via PD-1/PD-L1 blockade is a promising strategy to eradicate cancer cells. However, the PD-L1 pathological level is inconsistent with the therapeutic response and is not a reliable biomarker to stratify patients for anti-PD-1/PD-L1 therapy. Here, we describe patient sample deglycosylation
A novel humanized GLP-1 receptor model enables both affinity purification and Cre-LoxP deletion of the receptor
Jun LS, et al.
PLoS ONE, 9(4), e93746-e93746 (2014)
Identification and Characterization of a Novel Prokaryotic Peptide N-GLYCOSIDASE FROM ELIZABETHKINGIA MENINGOSEPTICA
Sun G, et al.
The Journal of Biological Chemistry, 290(12), 7452-7462 (2015)
Lucy S Jun et al.
PloS one, 9(4), e93746-e93746 (2014-04-04)
Class B G protein-coupled receptors (GPCRs) are important regulators of endocrine physiology, and peptide-based therapeutics targeting some of these receptors have proven effective at treating disorders such as hypercalcemia, osteoporosis, and type 2 diabetes mellitus (T2DM). As next generation efforts
Gabor Keresztes et al.
Vaccines, 10(2) (2022-02-27)
(1) Influenza viruses constantly change and evade prior immune responses, forcing seasonal re-vaccinations with updated vaccines. Current FDA-approved vaccine manufacturing technologies are too slow and/or expensive to quickly adapt to mid-season changes in the virus or to the emergence of
查看所有相关文献

商品

Strategies for Deglycosylating N-Linked Glycans

Explore strategies for releasing N-linked glycans with PNGase F, PNGase A & native & sequential deglycosylation with endoglycosidases & exoglycosidases.

Strategies for Deglycosylating N-Linked Glycans

Explore strategies for releasing N-linked glycans with PNGase F, PNGase A & native & sequential deglycosylation with endoglycosidases & exoglycosidases.

Strategies for Deglycosylating N-Linked Glycans

Explore strategies for releasing N-linked glycans with PNGase F, PNGase A & native & sequential deglycosylation with endoglycosidases & exoglycosidases.

Strategies for Deglycosylating N-Linked Glycans

Explore strategies for releasing N-linked glycans with PNGase F, PNGase A & native & sequential deglycosylation with endoglycosidases & exoglycosidases.

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门